Genentec, OSI Pharma Owe $67Million as False Claim Settlement for Lung Cancer Treatment Tarceva

Genentec, OSI Pharma Owe $67Million as False Claim Settlement for Lung Cancer Treatment Tarceva

South San Francisco based Genentech and OSI Pharmaceuticals based in Farmingdale, New York owe $67 million as a part of federal court settlement related to allegations over misleading claims which the companies made regarding a drug used for treating cancer.

OSI Pharmaceuticals, a part of Astellas Pharma and Genentech, a part of the Roche Group were taken to court after an ex-employee of Genentech alleged that the company gave misleading information to medical professionals as well as doctors.

However, nothing in the ruling reveals that the companies are officially accountable for the claims.

Tarceva, the drug under concern is approved for treating non-small-cell lung cancer and also advanced-stage of pancreatic cancer. A news release from the Department of Justice says, the complaint says the drug companies made doctors believe, the drug will work for the broad category of patient while in reality "there was little evidence to show that Tarceva was effective" for treating some patients who were suffering from non-small-cell lung cancer. The medicine worked only on a certain number of patients including those who did not smoke ever and people who carried a particular mutation in a protein which leads to the spread and growth of cancer cells.

According to the complaint, the companies did not report all the adverse effects that are connected to the use of this drug.

Companies: 
Region: 

Popular Stories